The initial oral dose for adults is 5 mg twice daily and gradually increases to 10 mg twice daily with an interval of at least 1 week. Based on individual patient response and tolerability, the dose can be increased up to the maximum dose of 15 mg twice daily with an interval of at least 1 week.

Mirogabalin is contraindicated in patients with known hypersensitivity to its components.

Mirogabalin may impair the ability to drive or operate machinery. Elderly people should be aware of falling and fracture.

Nasopharyngitis, somnolence, dizziness, peripheral edema and weight gain etc. may occur.

Co-administrated with OAT1, OAT3, OCT2, MATE1, MATE2-K or UGT inhibitors may increase Mirogabalin exposure, should be used with caution.

Use in pregnancy: There are no adequate and well-controlled studies with Mirogabalin in pregnant women to inform a drug-associated risk. Therefore, it should be used during pregnancy where there are no alternatives and benefits outweigh the risks.
Use in lactation: There are no data available on the excretion of Mirogabalin into human milk. A decision should be made to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.
Use in children & adolescents: The safety and effectiveness of Mirogabalin have not been established in patients under the age of 18 years.
Use in renal impairment: No dose adjustment is recommended in mild renal impairment. Reduce the 50% dose in moderate renal impairment. Reduce the 75% dose in severe renal impairment and End-Stage Renal Disease patients.
Use in hepatic impairment: No dose adjustment is recommended in mild or moderate hepatic impairment. No PK data of Mirogabalin are available for severe hepatic impairment patients.

Mirovan 2.5 Tablet: Each box contains 20 Tablets in a blister pack.
Mirovan 5 Tablet: Each box contains 20 Tablets in a blister pack.
Mirovan 10 Tablet: Each box contains 20 Tablets in a blister pack.